Literature DB >> 9795912

Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma.

R Idilman1, N De Maria, A Colantoni, D H Van Thiel.   

Abstract

Hepatocellular carcinoma (HCC) is estimated to have an annual worldwide incidence of 0.25 to 1.2 million new cases per year. Both the prevalence and incidence of HCC vary markedly as a function of geography and the local prevalence of chronic viral hepatitis. Both chronic hepatitis B and chronic hepatitis C are recognized as risk factors for HCC. The prevalence of cirrhosis in individuals with HCC and chronic hepatitis B or C is reported to be 80.9% and 75.8%, respectively. HCC occurs at a lower rate in chronic viral hepatitis in the absence of cirrhosis. Moreover, hepatitis C virus (HCV) rather than hepatitis B virus (HBV) is associated with the majority of non-cirrhotic cases of HCC. It is probable that the ongoing process of hepatocyte necrosis and liver cell renewal coupled with inflammation, which is characteristic of chronic viral hepatitis, causes not only nodular regeneration and cirrhosis but also progressive genomic errors in hepatocytes as well as unregulated growth and repair mechanisms leading to hepatocyte dysplasia and, in some cases, hepatic carcinoma. Current concepts concerning virus-induced HCC are reported and discussed in the following review.

Entities:  

Mesh:

Year:  1998        PMID: 9795912     DOI: 10.1046/j.1365-2893.1998.00116.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  27 in total

1.  No direct role for Epstein-Barr virus in American hepatocellular carcinoma.

Authors:  P G Chu; Y Y Chen; W Chen; L M Weiss
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

4.  Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.

Authors:  Waleed S Mohamed; Masoud M Omar; Tarek M Khayri; Ibrahim M Fakhr
Journal:  Int J Health Sci (Qassim)       Date:  2008-01

Review 5.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

6.  Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.

Authors:  Abeer A Bahnassy; Abdel-Rahman N Zekri; Ahmed El-Bastawisy; Amal Fawzy; Marwa Shetta; Nehal Hussein; Dalia Omran; Abdallah A S Ahmed; Samir S El-Labbody
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 7.  Fibrosis-dependent mechanisms of hepatocarcinogenesis.

Authors:  David Y Zhang; Scott L Friedman
Journal:  Hepatology       Date:  2012-06-29       Impact factor: 17.425

Review 8.  Risk factors for hepatocellular carcinoma in India.

Authors:  Premashis Kar
Journal:  J Clin Exp Hepatol       Date:  2014-04-13

Review 9.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

10.  Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation.

Authors:  D Y Jin; H L Wang; Y Zhou; A C Chun; K V Kibler; Y D Hou; H Kung; K T Jeang
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.